

27 November 2024

ASX Announcement

Results of Annual General Meeting

Firebrick Pharma Limited (ASX:FRE) (**Company** or **Firebrick**) advises it held its Annual General Meeting today, at 3.00pm (AEDT).

The resolutions were voted in accordance with the Notice of Annual General Meeting previously advised to the Australian Securities Exchange with all resolutions being passed on a poll.

Resolution 3 (Approval of 7.1A Mandate) and Resolution 4 (Amendment to Constitution) were passed by a sufficient majority as special resolutions.

Further information required by section 251AA(2) of the Corporations Act 2001 (Cth) is attached.

This announcement was authorised for release by Dr Peter Molloy, Executive Chairman, Firebrick Pharma Limited.

- ENDS -

About Firebrick (ASX:FRE)

Firebrick Pharma is a pharmaceutical innovator focused on developing and commercialising novel formulations and uses of povidone-iodine (www.firebrickpharma.com). The Company has successfully developed a povidone-iodine nasal spray, called Nasodine® Nasal Spray, and filed international trademarks and multiple patents on the product, including pharmaceutical formulation and use patents. The Company has also completed six clinical trials for the nasal spray, including a Phase 1 study, three Phase 2 studies and two Phase 3 studies, which have affirmed the product's safety and generally supported its efficacy as an antimicrobial nasal spray with utility in a range of clinical settings.

Media enquiries:

Heidi Cuthbert

+61 411 272 366

heidi.cuthbert@multiplier.com.au

Investor enquiries:

Investors@firebrickpharma.com

Disclosure of Proxy Votes

Firebrick Pharma Limited

Annual General Meeting

Wednesday, 27 November 2024



Automic

GPO Box 5193, Sydney, NSW 2001

P 1300 288 664 (aus) or +61 (0)2 9698 5414 (world)

F +61 (0)2 8583 3040 E hello@automic.com.au

ABN 27 152 260 814

In accordance with section 251AA of the Corporations Act 2001, the following information is provided in relation to resolutions put to members at the meeting.

			Proxy Votes				Poll Results (if applicable)			Results
Resolution	Decided by Show of Hands (S) or Poll (P)	Total Number of Proxy Votes exercisable by proxies validly appointed	FOR	AGAINST	ABSTAIN	PROXY'S DISCRETION	FOR	AGAINST	ABSTAIN	OUTCOME
1 ADOPTION OF REMUNERATION REPORT	P	15,962,684	14,794,723 92.68%	316,138 1.98%	122,809	851,823 5.34%	15,646,546 98.02%	316,138 1.98%	122,809	-
2 RE-ELECTION OF DIRECTOR – STEPHEN FRANCIS GOODALL	P	78,933,448	77,904,486 98.70%	177,139 0.22%	1,352	851,823 1.08%	79,356,309 99.78%	177,139 0.22%	1,352	Carried
3 APPROVAL OF 7.1A MANDATE	P	78,689,865	77,607,821 98.62%	227,642 0.29%	244,935	854,402 1.09%	79,062,223 99.71%	227,642 0.29%	244,935	Carried
4 AMENDMENT TO CONSTITUTION	P	78,826,028	77,855,586 98.77%	116,919 0.15%	108,772	853,523 1.08%	79,309,109 99.85%	116,919 0.15%	108,772	Carried
5 RATIFICATION OF PRIOR ISSUE OF PLACEMENT SHARES	P	78,932,569	77,925,823 98.72%	154,923 0.20%	2,231	851,823 1.08%	79,377,646 99.81%	154,923 0.19%	2,231	Carried
6 RATIFICATION OF PRIOR ISSUE OF PLACEMENT OPTIONS	P	78,932,569	77,925,823 98.72%	154,923 0.20%	2,231	851,823 1.08%	79,377,646 99.81%	154,923 0.19%	2,231	Carried
7 RATIFICATION OF PRIOR ISSUE OF CONSULTANT OPTIONS	P	78,911,748	77,896,586 98.71%	163,339 0.21%	23,052	851,823 1.08%	79,348,409 99.79%	163,339 0.21%	23,052	Carried
8 RATIFICATION OF PRIOR ISSUE OF SHORTFALL PLACEMENT SHARES	P	73,822,970	72,817,557 98.64%	153,590 0.21%	25,264	851,823 1.15%	74,269,380 99.79%	153,590 0.21%	25,264	Carried



			Proxy Votes				Poll Results (if applicable)			Results
Resolution	Decided by Show of Hands (S) or Poll (P)	Total Number of Proxy Votes exercisable by proxies validly appointed	FOR	AGAINST	ABSTAIN	PROXY'S DISCRETION	FOR	AGAINST	ABSTAIN	OUTCOME
9 APPOINTMENT OF AUDITOR	P	78,933,448	78,079,183 98.92%	742 0.00%	1,352	853,523 1.08%	79,532,706 100.00%	742 0.00%	1,352	Carried

